AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19136752 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal block with bupivacaine and sufentanil combination
Number of subjects: 30
Study 19136752 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 30
Study 18027161 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline FEV(1)/FVC ratio<0.7
Number of subjects: 3041
Study 18027161 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline airflow obstruction and FEV(1)<60%
Number of subjects: 3041
Study 15466899 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological intervention (motivational interviewing, coping skills training, social support)
Number of subjects: 91
Study 15466899 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 91
Study 11605555 — intervention group
Group type: EXPERIMENTAL
Intervention: Confidence judgments required after each comparative judgment (sessions 5-8)
Number of subjects: 0
Study 11605555 — intervention group
Group type: COMPARATOR
Intervention: No confidence judgments required (sessions 1-4 and 9-12)
Number of subjects: 0
Study 11605555 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-alternative comparative judgments of Canadian city populations
Number of subjects: 0
Study 9851505 — intervention group
Group type: EXPERIMENTAL
Intervention: EESC‐DCR
Number of subjects: 60
Study 9851505 — intervention group
Group type: COMPARATOR
Intervention: EXT‐DCR
Number of subjects: 60
Study 8133476 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim sulfate 0.1%/polymyxin B sulfate
Number of subjects: 99
Study 8133476 — intervention group
Group type: COMPARATOR
Intervention: Tobramycin 0.3%
Number of subjects: 99
Study 2553235 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly doxorubicin (ADR)
Number of subjects: 102
Study 2553235 — intervention group
Group type: COMPARATOR
Intervention: Triweekly doxorubicin (ADR)
Number of subjects: 102
Study 960908 — intervention group
Group type: EXPERIMENTAL
Intervention: +)-cyanidanol-3 (2 g daily, administered orally)
Number of subjects: 28
Study 960908 — intervention group
Group type: COMPARATOR
Intervention: +)-cyanidanol-3 (1 g daily)
Number of subjects: 28
Study 31744425 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical thrombectomy (MT) with Trevo stent retriever
Number of subjects: 107
Study 31744425 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 107
Study 31744425 — intervention group
Group type: COMPARATOR
Intervention: >=3 passes with stent retriever
Number of subjects: 107
Study 31744425 — intervention group
Group type: COMPARATOR
Intervention: Baseline National Institutes of Health Stroke Scale score >17
Number of subjects: 107
Study 31315799 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracutaneous suturing
Number of subjects: 280
Study 31315799 — intervention group
Group type: COMPARATOR
Intervention: Stapling
Number of subjects: 280
Study 25184738 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated refundable tax credit
Number of subjects: 130
Study 25184738 — intervention group
Group type: COMPARATOR
Intervention: Control group (no tax credit)
Number of subjects: 130
Study 23945134 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ) 4 or 8 mg/kg every four weeks
Number of subjects: 585
Study 23945134 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 585
Study 23945134 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline C1M levels
Number of subjects: 585
Study 21861607 — intervention group
Group type: EXPERIMENTAL
Intervention: Safer Sex Skills Building (SSB) intervention
Number of subjects: 515
Study 21861607 — intervention group
Group type: EXPERIMENTAL
Intervention: Female condom demonstration session
Number of subjects: 515
Study 19965519 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-beta 1a (intramuscular)
Number of subjects: 24
Study 19965519 — intervention group
Group type: COMPARATOR
Intervention: Previous interferon-beta preparation (subcutaneous)
Number of subjects: 24
Study 17978323 — intervention group
Group type: EXPERIMENTAL
Intervention: In-patient treatment
Number of subjects: 167
Study 17978323 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialist out-patient treatment
Number of subjects: 167
Study 17978323 — intervention group
Group type: COMPARATOR
Intervention: General CAMHS treatment
Number of subjects: 167
Study 17978323 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall recovery rates
Number of subjects: 167
Study 14967215 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapheme-phoneme convergence
Number of subjects: 14
Study 14967215 — intervention group
Group type: COMPARATOR
Intervention: Visual orthographic factors
Number of subjects: 14
Study 11329564 — intervention group
Group type: EXPERIMENTAL
Intervention: Esophagogastric dissociation (EGD)
Number of subjects: 29
Study 11329564 — intervention group
Group type: COMPARATOR
Intervention: Fundoplication and gastrostomy
Number of subjects: 29
Study 9494148 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg orally per day
Number of subjects: 541
Study 9494148 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg orally per day
Number of subjects: 541
Study 9494148 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 150 mg orally twice a day
Number of subjects: 541
Study 9494148 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg per day (maintenance)
Number of subjects: 541
Study 9494148 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 150 mg twice a day (maintenance)
Number of subjects: 541
Study 8307222 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid/dipyridamole (50 mg/400 mg daily)
Number of subjects: 223
Study 8307222 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 223
Study 3144173 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetate (160 mmol acetate/d replacing 160 mmol chloride/d)
Number of subjects: 12
Study 3144173 — intervention group
Group type: COMPARATOR
Intervention: No added acetate
Number of subjects: 12
Study 30884964 — intervention group
Group type: EXPERIMENTAL
Intervention: 3‐OHB infusion
Number of subjects: 16
Study 27798513 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (EVL) with target trough level (Ctrough, 3‐8 ng/mL), prednisone, and tacrolimus (TCL) (target Ctrough, 2‐5 ng/mL)
Number of subjects: 16
Study 27798513 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (EVL)
Number of subjects: 16
Study 26501937 — intervention group
Group type: EXPERIMENTAL
Intervention: PDS group (n=15)
Number of subjects: 30
Study 26501937 — intervention group
Group type: COMPARATOR
Intervention: Non-PDS group (n=15)
Number of subjects: 30
Study 25475464 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal medical management (OMT)
Number of subjects: 1192
Study 25475464 — intervention group
Group type: COMPARATOR
Intervention: Initial revascularization plus OMT
Number of subjects: 1192
Study 25475464 — intervention group
Group type: EXPERIMENTAL
Intervention: Severity of angina during the first 6 months
Number of subjects: 1192
Study 22582933 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotropic medications (specific drugs not mentioned)
Number of subjects: 0
Study 22582933 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19545249 — intervention group
Group type: EXPERIMENTAL
Intervention: MAP0004 0.5 mg
Number of subjects: 86
Study 19545249 — intervention group
Group type: EXPERIMENTAL
Intervention: MAP0004 1.0 mg
Number of subjects: 86
Study 19545249 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 19545249 — intervention group
Group type: EXPERIMENTAL
Intervention: MAP0004
Number of subjects: 86
Study 17314579 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.3%, 3 mL)
Number of subjects: 40
Study 17314579 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 40
Study 15377581 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-tracking (FT) group
Number of subjects: 207
Study 15377581 — intervention group
Group type: COMPARATOR
Intervention: Routine group (Control)
Number of subjects: 207
Study 11474143 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensorial saturation (SS)
Number of subjects: 17
Study 11474143 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% oral glucose plus sucking
Number of subjects: 17
Study 11474143 — intervention group
Group type: COMPARATOR
Intervention: Control (no analgesia)
Number of subjects: 17
Study 9684795 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant activated factor VII (rFVIIa) injection, doses ranging from 5 to 320 microg/kg
Number of subjects: 28
Study 9684795 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant activated factor VII (rFVIIa) injection, doses < or = 20 microg/kg
Number of subjects: 28
Study 9684795 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant activated factor VII (rFVIIa) injection, doses > 20 microg/kg
Number of subjects: 28
Study 9684795 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant activated factor VII (rFVIIa) injection
Number of subjects: 28
Study 7766962 — intervention group
Group type: EXPERIMENTAL
Intervention: Food A (3.12 g protein equivalent per 100 kcal)
Number of subjects: 25
Study 7766962 — intervention group
Group type: COMPARATOR
Intervention: Food B (2.74 g protein equivalent per 100 kcal)
Number of subjects: 25
Study 7766962 — intervention group
Group type: EXPERIMENTAL
Intervention: Food A
Number of subjects: 25
Study 7766962 — intervention group
Group type: COMPARATOR
Intervention: Food B
Number of subjects: 25
Study 3144009 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein supply (1 g protein/kg.d) and 1-carnitine (2 g/day)
Number of subjects: 14
Study 3144009 — intervention group
Group type: COMPARATOR
Intervention: Placebo (same regimen as treated group)
Number of subjects: 14
Study 3144009 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein supply and 1-carnitine
Number of subjects: 14
Study 3144009 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 31610383 — intervention group
Group type: EXPERIMENTAL
Intervention: BISQ-R scoring algorithm applied to data sample 1 (33,835 submissions)
Number of subjects: 33835
Study 31610383 — intervention group
Group type: EXPERIMENTAL
Intervention: BISQ-R scoring algorithm applied to data sample 2 (16,531 submissions)
Number of subjects: 33835
Study 31610383 — intervention group
Group type: EXPERIMENTAL
Intervention: BISQ-R scoring algorithm applied to data sample 3 (web-based ecology study)
Number of subjects: 33835
Study 31610383 — intervention group
Group type: EXPERIMENTAL
Intervention: BISQ-R scoring algorithm applied to data sample 4 (longitudinal study)
Number of subjects: 33835
Study 31610383 — intervention group
Group type: EXPERIMENTAL
Intervention: BISQ-R scoring algorithm applied to data sample 5 (randomized control trial behavioral intervention study)
Number of subjects: 33835
Study 28343938 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone (T) administered 2-3 hours prior to testing
Number of subjects: 16
Study 28343938 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered 2-3 hours prior to testing
Number of subjects: 16
Study 23952097 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous paracetamol (1 g IV every 8 hours for up to 24 hours)
Number of subjects: 100
Study 23952097 — intervention group
Group type: COMPARATOR
Intervention: Placebo (physiologic saline every 8 hours for up to 24 hours)
Number of subjects: 100
Study 23731246 — intervention group
Group type: EXPERIMENTAL
Intervention: aPCC prophylaxis
Number of subjects: 19
Study 20147742 — intervention group
Group type: EXPERIMENTAL
Intervention: EpCAM+CK+CD45- objects
Number of subjects: 179
Study 20147742 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction model including large tumor cell fragments (L-TCF), age, hemoglobin and lactate dehydrogenase
Number of subjects: 179
Study 20147742 — intervention group
Group type: EXPERIMENTAL
Intervention: Models with S-TMP or CTC instead of L-TCF
Number of subjects: 179
Study 18538990 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone interview
Number of subjects: 1690
Study 18538990 — intervention group
Group type: COMPARATOR
Intervention: Mail interview
Number of subjects: 1690
Study 15695937 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based walking program
Number of subjects: 90
Study 12552047 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke Impact Scale-16 (SIS-16)
Number of subjects: 621
Study 12552047 — intervention group
Group type: COMPARATOR
Intervention: Barthel Index (BI)
Number of subjects: 621
Study 11763907 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0% ZCT essential oil dentifrice
Number of subjects: 196
Study 11763907 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0% ZCT essential oil dentifrice
Number of subjects: 196
Study 11763907 — intervention group
Group type: COMPARATOR
Intervention: Crest Regular dentifrice
Number of subjects: 196
Study 8857096 — intervention group
Group type: EXPERIMENTAL
Intervention: 4F catheter/sheath system
Number of subjects: 244
Study 8157902 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (bolus i.v. of 1 mg/kg, followed by an infusion of 4 mg/min)
Number of subjects: 60
Study 8157902 — intervention group
Group type: COMPARATOR
Intervention: Placebo (infusion of saline at a rate of 1 mL/min)
Number of subjects: 60
Study 3530156 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (10 mg base kg-1)
Number of subjects: 282
Study 3530156 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorproguanil (1.5 mg kg-1)
Number of subjects: 282
Study 3530156 — intervention group
Group type: COMPARATOR
Intervention: Pyrimethamine
Number of subjects: 282
Study 3530156 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vitamin tablets)
Number of subjects: 282
Study 3530156 — intervention group
Group type: COMPARATOR
Intervention: Untreated group from the fifth village
Number of subjects: 282
Study 28884824 — intervention group
Group type: EXPERIMENTAL
Intervention: Anacetrapib (5 to 500 mg)
Number of subjects: 8
Study 28884824 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 24446988 — intervention group
Group type: EXPERIMENTAL
Intervention: Differential training
Number of subjects: 14
Study 24446988 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional training
Number of subjects: 14
Study 22468572 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Psychodynamic Interpersonal Psychotherapy (GPIP)
Number of subjects: 95
Study 22468572 — intervention group
Group type: COMPARATOR
Intervention: Group Cognitive Behavioral Therapy (GCBT)
Number of subjects: 95
Study 20004542 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan (300mg)
Number of subjects: 36
Study 20004542 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (12.5mg)
Number of subjects: 36
Study 17122980 — intervention group
Group type: EXPERIMENTAL
Intervention: RF-assisted laparoscopic liver resection (LLR)
Number of subjects: 45
Study 17122980 — intervention group
Group type: COMPARATOR
Intervention: Non RF-assisted laparoscopic liver resection (LLR)
Number of subjects: 45
Study 15691261 — intervention group
Group type: EXPERIMENTAL
Intervention: VapoMeter
Number of subjects: 0
Study 15691261 — intervention group
Group type: COMPARATOR
Intervention: Tewameter
Number of subjects: 0
Study 15691261 — intervention group
Group type: EXPERIMENTAL
Intervention: Both devices
Number of subjects: 0
Study 12100701 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol propionate foam
Number of subjects: 81
Study 12100701 — intervention group
Group type: COMPARATOR
Intervention: Placebo foam
Number of subjects: 81
Study 10500310 — intervention group
Group type: EXPERIMENTAL
Intervention: MTHFR C677T mutation
Number of subjects: 95
Study 10500310 — intervention group
Group type: EXPERIMENTAL
Intervention: Age and BMI
Number of subjects: 95
Study 10500310 — intervention group
Group type: COMPARATOR
Intervention: Serum total homocysteine and MTHFR polymorphism
Number of subjects: 95
Study 8906937 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical flurbiprofen
Number of subjects: 90
Study 8906937 — intervention group
Group type: COMPARATOR
Intervention: Betamethasone
Number of subjects: 90
Study 2651233 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 30 mg/day
Number of subjects: 2276
Study 2651233 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine titrated to 60 mg/day
Number of subjects: 2276
Study 2651233 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2276
Study 793562 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextroamphetamine sulfate, 20 mg orally daily at 8 PM
Number of subjects: 0
Study 793562 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextroamphetamine sulfate, up to 40 mg orally
Number of subjects: 0
Study 793562 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextroamphetamine sulfate
Number of subjects: 0
Study 31486726 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led telephonic case management
Number of subjects: 9
Study 31486726 — intervention group
Group type: COMPARATOR
Intervention: Specialty outpatient palliative care
Number of subjects: 9
Study 27342301 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized cognitive intervention (23 ALL/11 BT)
Number of subjects: 68
Study 27342301 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group (24 ALL/10 BT)
Number of subjects: 68
Study 27342301 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized cognitive intervention
Number of subjects: 68
Study 26007292 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-tooth tenaculum
Number of subjects: 80
Study 26007292 — intervention group
Group type: EXPERIMENTAL
Intervention: Vulsellum
Number of subjects: 80
Study 23528880 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive group program (psychoeducation, cognitive rehabilitation, cognitive behavioral therapy)
Number of subjects: 84
Study 23528880 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 84
Study 23528880 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive group program
Number of subjects: 84
Study 22204420 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 weeks individualised nutritional counselling by a registered dietician complemented with follow‐up by general practitioners
Number of subjects: 160
Study 22204420 — intervention group
Group type: COMPARATOR
Intervention: 12 weeks follow‐up by general practitioners alone
Number of subjects: 160
Study 19735564 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured information programme for nursing staff, information materials for legal guardians and residents' relatives, and a one-day training workshop for nominated nurses.
Number of subjects: 3000
Study 19735564 — intervention group
Group type: COMPARATOR
Intervention: Standard information (control group).
Number of subjects: 3000
Study 16526585 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually prescribed activities
Number of subjects: 30
Study 15454375 — intervention group
Group type: EXPERIMENTAL
Intervention: CardioVention system (hybrid pump)
Number of subjects: 10
Study 15454375 — intervention group
Group type: COMPARATOR
Intervention: Conventional on-pump surgery
Number of subjects: 10
Study 11092795 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Assessment Questionnaire (HAQ)
Number of subjects: 0
Study 11092795 — intervention group
Group type: EXPERIMENTAL
Intervention: SF-36 (generic measure)
Number of subjects: 0
Study 11092795 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain score
Number of subjects: 0
Study 9396958 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (20 Hz at 80% motor threshold)
Number of subjects: 12
Study 9396958 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 12
Study 8333598 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute dose of alcohol
Number of subjects: 0
Study 3447334 — intervention group
Group type: EXPERIMENTAL
Intervention: Subconjunctival 5-fluorouracil (5-FU)
Number of subjects: 0
Study 3447334 — intervention group
Group type: COMPARATOR
Intervention: No antimetabolite treatment
Number of subjects: 0
Study 29414735 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) with topical application of 50 μl toluidine blue (1 mg/ml) followed by laser irradiation using GaAlAs laser (630 nm, 10 mW/cm2)
Number of subjects: 45
Study 29414735 — intervention group
Group type: EXPERIMENTAL
Intervention: Low level laser therapy (LLLT) using diode laser (630 nm, 10 mW)
Number of subjects: 45
Study 29414735 — intervention group
Group type: COMPARATOR
Intervention: Topical corticosteroid application (dexamethasone 0.5 mg in 5 ml water mouthwash for 5 min)
Number of subjects: 45
Study 27437665 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe low flow (SLF) group
Number of subjects: 984
Study 27437665 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate low flow (MLF) group
Number of subjects: 984
Study 27437665 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal flow (NF) group
Number of subjects: 984
Study 27437665 — intervention group
Group type: EXPERIMENTAL
Intervention: MLF group
Number of subjects: 984
Study 27437665 — intervention group
Group type: EXPERIMENTAL
Intervention: NF group
Number of subjects: 984
Study 27437665 — intervention group
Group type: EXPERIMENTAL
Intervention: SLF group
Number of subjects: 984
Study 27437665 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent predictors of 1-year mortality
Number of subjects: 984
Study 24572083 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted CITI ethics certification training module
Number of subjects: 40
Study 24572083 — intervention group
Group type: COMPARATOR
Intervention: Standard CITI ethics certification training module
Number of subjects: 40
Study 22906262 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg tamsulosin plus 0.5 mg dutasteride
Number of subjects: 216
Study 22906262 — intervention group
Group type: COMPARATOR
Intervention: 0.2 mg tamsulosin
Number of subjects: 216
Study 20876171 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized epinephrine plus oral dexamethasone
Number of subjects: 0
Study 20876171 — intervention group
Group type: COMPARATOR
Intervention: No active treatment
Number of subjects: 0
Study 20876171 — intervention group
Group type: COMPARATOR
Intervention: Nebulized epinephrine alone
Number of subjects: 0
Study 20876171 — intervention group
Group type: COMPARATOR
Intervention: Oral dexamethasone alone
Number of subjects: 0
Study 18722297 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Hip Arthroplasty (THA)
Number of subjects: 40